Cooper Earnings Reports

CooperCompanies reported Q1 2025 revenue of $964.7 million, a 4% increase year-over-year. The company saw growth across its divisions, with CooperVision revenue up 4% to $646.1 million and CooperSurgical revenue up 3% to $318.6 million. GAAP net income reached $104.3 million, translating to diluted EPS of $0.52, while non-GAAP EPS came in at $0.92. Operating income was $182.0 million, with a 19% operating margin. Free cash flow stood at $101.2 million, driven by strong operational performance.

CooperCompanies reported strong Q4 2024 results, with revenue reaching $1,018.4 million, a 10% increase year-over-year. GAAP EPS increased by 38% to $0.58, and non-GAAP EPS rose by 19% to $1.04.

CooperCompanies announced an 8% increase in revenue to $1,002.8 million for Q3 2024. GAAP EPS increased by 22% to $0.52, and non-GAAP EPS increased by 14% to $0.96. The company raised its fiscal year 2024 financial guidance.

CooperCompanies announced its second quarter 2024 results with a 7% increase in revenue year-over-year, reaching $942.6 million. GAAP EPS increased by 122% to $0.44, and non-GAAP EPS increased by 10% to $0.85. The company has raised its fiscal year 2024 financial guidance.

CooperCompanies announced strong Q1 2024 results with record quarterly revenues of $931.6 million, a 9% increase year-over-year. CooperVision revenue grew by 7% and CooperSurgical revenue grew by 12%. The company's non-GAAP EPS increased by 18% to $0.85.

CooperCompanies announced Q4 2023 results with revenue of $927.1 million, up 9% organically. GAAP EPS was $1.70, up 29%, and non-GAAP EPS was $3.47, up 26%. The company's FY 2023 revenue reached $3.6 billion, up 10% organically.

CooperCompanies announced a 10% increase in revenue to $930.2 million. GAAP diluted EPS was $1.71, while non-GAAP diluted EPS reached $3.35. The company's performance was driven by strong results from both CooperVision and CooperSurgical.

CooperCompanies reported a 6% increase in revenue to $877.4 million, with CooperVision and CooperSurgical showing growth. However, GAAP diluted EPS decreased by 69% to $0.80, while non-GAAP diluted EPS decreased by 5% to $3.08.

CooperCompanies announced a 9% increase in revenue to $858.5 million. GAAP diluted EPS was $1.70, while non-GAAP diluted EPS was $2.90. The company's CooperVision and CooperSurgical segments showed revenue increases of 4% and 23%, respectively.

CooperCompanies announced its Q4 and full year 2022 results, with Q4 revenue increasing by 12% to $848.1 million. GAAP diluted EPS for the quarter was $1.32, a decrease of 40% compared to the previous year. The company closed the fiscal year with record annual revenue driven by gains in contact lenses and fertility.

CooperCompanies announced its fiscal third quarter results with revenue increasing by 10% year-over-year to $843.4 million. CooperVision's revenue increased by 2% to $566.3 million, while CooperSurgical's revenue increased by 35% to $277.1 million. GAAP diluted earnings per share were $1.98, and non-GAAP diluted earnings per share were $3.19.

CooperCompanies announced strong second quarter results with revenue up 15% year-over-year to $829.8 million. Both CooperVision and CooperSurgical showed strong revenue growth. GAAP diluted earnings per share increased to $2.55, while non-GAAP diluted earnings per share decreased to $3.24.

CooperCompanies announced strong first quarter results with revenue up 16% year-over-year to $787.2 million. CooperVision revenue increased by 11% and CooperSurgical revenue increased by 30%. GAAP diluted earnings per share were $1.91, while non-GAAP diluted earnings per share were $3.24, a 2% increase from the previous year.

CooperCompanies announced strong Q4 and full-year 2021 results, with Q4 revenue up 11% year-over-year to $759.1 million and GAAP EPS up 35% to $2.21. The company achieved record annual revenue, profits, and cash flow, driven by market share gains in contact lenses and fertility.

CooperCompanies announced a strong third quarter with revenue increasing by 32% year-over-year to $763.4 million. Both CooperVision and CooperSurgical experienced record revenues, contributing to record earnings and robust free cash flow. GAAP diluted earnings per share reached $12.37, while non-GAAP diluted earnings per share was $3.41, a 50% increase from the previous year.

CooperCompanies announced strong second-quarter results with revenue up 37% year-over-year to $719.5 million. Both CooperVision and CooperSurgical posted all-time record quarterly revenues, driving record quarterly earnings. The company has updated its fiscal year 2021 financial guidance.

CooperCompanies announced its Q1 2021 financial results, with revenue up 5% year-over-year to $680.5 million. GAAP diluted earnings per share were $42.31, and non-GAAP diluted earnings per share were $3.17, an 18% increase from the previous year. The company initiated fiscal year 2021 guidance, expressing enthusiasm for future prospects.

CooperCompanies reported a decrease in revenue by 1% year-over-year to $681.6 million. The GAAP diluted EPS was $1.64, a decrease of 32% from the previous year's fourth quarter, while the non-GAAP diluted EPS was $3.16, down by 4%.

CooperCompanies reported a 15% year-over-year decrease in revenue to $578.2 million. GAAP diluted earnings per share were $1.12, a 53% decrease, and non-GAAP diluted earnings per share were $2.28, a 30% decrease. The company experienced a faster than expected recovery as the quarter progressed.

CooperCompanies reported a 20% decrease in revenue to $524.9 million, with GAAP diluted earnings per share down 91% to $0.23 and non-GAAP diluted earnings per share down 48% to $1.51 compared to the same quarter last year. The company experienced a decrease in revenue for both CooperVision and CooperSurgical segments.

CooperCompanies reported a 3% increase in revenue to $646.2 million. GAAP diluted earnings per share decreased by 12% to $1.82, and Non-GAAP diluted earnings per share decreased by 7% to $2.69.